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Running title 
Behavioural and psychological symptoms of dementia in Down syndrome 
Abstract 
Behavioural and Psychological Symptoms of Dementia (BPSD) are a core symptom of dementia and are 
associated with suffering, earlier institutionalization and accelerated cognitive decline for patients and 
increased caregiver burden. Despite the extremely high risk for Down syndrome (DS) individuals to develop 
dementia, BPSD have not been comprehensively assessed in the DS population. Due to the great variety of DS 
cohorts, diagnostic methodologies, sub-optimal scales, covariates and outcome measures, it is questionable 
whether BPSD have always been accurately assessed. However, accurate recognition of BPSD may increase 
awareness and understanding of these behavioural aberrations, thus enabling adaptive caregiving and, 
importantly, allowing for therapeutic interventions. Particular BPSD can be observed (long) before the clinical 
dementia diagnosis and could therefore serve as early indicators of those at risk, and provide a new, noninvasive 
way to monitor, or at least give an indication of, the complex progression to dementia in DS. 
Therefore, this review summarizes and evaluates the rather limited knowledge on BPSD in DS and highlights its 
importance and potential for daily clinical practice. 
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1. Introduction: Down syndrome and Alzheimer’s disease – a disruptive marriage 
Intellectual disability, previously referred to as mental retardation, is defined as ‘a significantly 
reduced ability to understand new or complex information and to learn and apply new skills’ (World Health  
Organization, 2014) and reaches a prevalence of approximately 1% in the Western population (Maulik, 
Mascarenhas, Mathers, Dua, & Saxena, 2011). The most common genetic cause of human intellectual disability 
is Down syndrome (DS), caused by the triplication of the human chromosome 21 (HSA21). DS, or trisomy 21, is 
present in approximately 1 in 650-1000 live births and this prevalence has not decreased over the years, 
despite an increase in medical terminations (Bittles, Bower, Hussain, & Glasson, 2007; Parker et al., 2010). 
Down syndrome was named after the nineteenth-century medical doctor John Langdon Down. In his 
report ‘Observations on an Ethnic Classification of Idiots’ (1866), Langdon Down addressed their pronounced 
features, including the characteristic facial appearance, behaviour and distinct cognitive problems (Down, 
1866). The most marked cognitive features are the strongly reduced IQ that ranges from 30 to 70 with an 
average value of 50 (Vicari, 2004), associated with reduced brain volumes, including hippocampus (Beacher et 
al., 2010; Pinter et al., 2001; Schmidt-Sidor, Wisniewski, Shepard, & Sersen, 1990), and hippocampal 
dysfunction, which likely relates to the impairment in verbal short-term memory and hippocampus-mediated 
explicit long-term memory that are usually present in DS (Lott & Dierssen, 2010; Pennington, Moon, Edgin, 
Stedron, & Nadel, 2003). 
In addition to the congenital intellectual disability, people with DS face accelerated ageing, including 
early-onset dementia due to Alzheimer’s disease (AD) (Zigman, 2013). An estimated 50-70% of DS individuals 
develop AD by the time they reach 60-70 years of age (Zigman & Lott, 2007). In contrast, AD is present in 
about 11% of the general population of 65 years and older (Alzheimer’s Assocation, 2015). Although studies 
have implicated various HSA21 gene products, such as the synapse-associated synaptojanin 1 protein (Arai, 
Ijuin, Takenawa, Becker, & Takashima, 2002; Cossec et al., 2012; Martin et al., 2014), the strongly increased 
risk of AD in DS is predominantly attributed to the overexpression of the HSA21-encoded amyloid precursor 
protein (APP) gene, the precursor of amyloid-β (Aβ), which, in turn, forms the main constituent of the typical 
AD plaques (Ness et al., 2012). Strikingly, pathological studies revealed that extensive deposition of Aβ 
plaques, as well as neuroinflammation and substantial numbers of neurofibrillary tangles, are present in 
virtually all DS individuals aged 40 years and older, twenty to thirty years earlier than in the general population 
at risk of AD (Mann, Yates, Marcyniuk, & Ravindra, 1986; Mann, 1988; Piessens & Overweg, 1971; Wilcock, 
2012; Wisniewski, Wisniewski, & Wen, 1985). 
Whereas AD-like neuropathology in DS is thus omnipresent around mid-life, the onset of clinical 
dementia symptoms is subject to pronounced variation in time and approximately 30-50% of the DS 
population aged 60-70 years has not developed clinical dementia (reviewed in: Zigman and Lott, 2007). This 
highly variable time window between the presence of neuropathology and onset of clinical dementia 
symptoms makes the prediction of the course to dementia a fairly complex endeavour. In addition, the 
identification of early changes in cognitive functioning is complicated by the (variable degree of) congenital 
intellectual disability in DS (Devenny, Krinsky-McHale, Sersen, & Silverman, 2000; Oliver, Crayton, Holland, 
Hall, & Bradbury, 1998; Prasher, 2009). Despite these difficulties, predicting and monitoring the progression of 
AD dementia in DS is one of the major challenges in clinical practice and of utmost importance to enable 
adaptive caretaking and therapeutic interventions. 
Although auspicious results have been obtained in recent studies on early diagnostic serum 
biomarkers (Dekker et al., 2015), plasma Aβ (Coppus et al., 2012; Schupf et al., 2010) and telomere shortening 
(Jenkins et al., 2010, 2012), an established clinical procedure with fairly easy repeatability and limited 
invasiveness to predict conversion to AD dementia is not yet available. In that respect, behavioural and 
psychological symptoms of dementia (BPSD) are of great interest, i.e. ‘signs and symptoms of disturbed 
perception, thought content, mood, or behaviour that frequently occur in patients with dementia’ (Finkel, 
Costa e Silva, Cohen, Miller, & Sartorius, 1996). BPSD are found in all types of dementia and are among the 
core symptoms, in addition to cognitive decline and impaired activities of daily living (Finkel et al., 1996; Finkel, 
2000). For instance, 80-97% of the AD patients in the general population suffer from one or more BPSD at 
some point during their disease (Gauthier et al., 2010). 
Jost & Grossberg (1996) investigated the temporal relationship between BPSD and the clinical 
diagnosis of AD and showed that particular BPSD can be acquired before, around or after the AD diagnosis. 
Social withdrawal, for instance, preceded the clinical diagnosis of AD by an average of 33 months, whilst 
agitation, aggression and hallucinations were generally observed 1-2 years after AD diagnosis. Recently, we 
evaluated BPSD in mild cognitive impairment (MCI), i.e. a cognitive state between normal aging and dementia, 
and found that BPSD were more commonly present in AD than in MCI patients (Van der Mussele et al., 2013b). 
Three behavioural syndromes were identified in both MCI and AD patients: a depression, an agitation and a 
psychosis syndrome. Depressive symptoms were most dominant in MCI, whereas AD patients were more 
subjected to agitation (Van der Mussele, Le Bastard, et al., 2014; Van der Mussele, Mariën, et al., 2014a). The 
presence of depressive symptoms in MCI was strongly associated with progression to AD in the general 
population (Van der Mussele, Fransen, et al., 2014). 
As such, assessment of BPSD might offer a clinical tool to herald the onset of dementia and monitor 
its progression in DS as well. Already in 1948, George Jervis, a medical doctor in Thiells (New York), 
commented on the marked changes in DS subjects with early ‘senile’ dementia: ‘In the few mongoloid idiots 
who reach the fourth or fifth decade of life, remarkable personality changes may occur, resulting from 
intellectual and emotional deterioration’ (Jervis, 1948). Surprisingly, despite such reports and the high risk to 
develop AD at a relatively early age in DS, the relationship between AD and behavioural and psychological 
alterations in this syndrome has been largely neglected so far. 
Whereas a substantial amount of studies investigated particular behavioural disturbances in DS, 
whether or not in relation to the status of dementia, few studies comprehensively assessed BPSD in DS using 
an integrated approach. Such an approach, i.e. looking at a series of behavioural and psychological changes 
over time in relation to the onset of clinical dementia symptoms, is essential to improve understanding of the 
temporal relationship between BPSD and AD in DS. Moreover, accurate identification of BPSD may improve 
early identification of those at risk, yield novel treatment possibilities and thus improve quality of life, as well 
as provide a new, non-invasive way to monitor, or at least give an indication of, the complex progression to 
dementia in DS. Therefore, this review aims to summarize and evaluate the rather limited knowledge on BPSD 
in DS and highlight its importance and potential for daily clinical practice. 
2. Behavioural and psychological symptoms of dementia (BPSD) 
BPSD, or in a narrower sense also known as neuropsychiatric symptoms (NPS), are defined as ‘a 
heterogeneous range of psychological reactions, psychiatric symptoms and behaviours resulting from the 
presence of dementia’ (Finkel, 2001; Lyketsos et al., 2011). Even though BPSD have been intensively studied 
during the last two decades, they are far from being a newly recognized entity. Already in 1906, Alois 
Alzheimer described hallucinations, delusions, paranoia and agitation in his famous 51-year old patient 
Auguste Deter, who suffered from a particular form of dementia that later became known as Alzheimer’s 
disease (Maurer, Volk, & Gerbaldo, 1997). 
This heterogeneous group of BPSD is associated with increased suffering, a reduced quality of life, 
increased risk of mortality, accelerated cognitive decline and earlier institutionalization for patients, severe 
burden for caregivers and relatives, and increased financial costs (Finkel et al., 1996; Finkel, 2001), and can be 
assessed and categorized in various ways. More than two dozen scales are available for BPSD in AD and other 
dementia syndromes in the general population (Finkel, 2000). The most commonly used are the Behavioural 
Pathology in Alzheimer's Disease Rating Scale (BEHAVE-AD) (Reisberg et al., 1987; Reisberg, Auer, & Monteiro, 
1996) and the Neuropsychiatric Inventory (NPI) (Cummings, 1997; Cummings et al., 1994). 
The behavioural and psychological items in the BEHAVE-AD and NPI largely correspond (Table 1) and 
will be used hereafter to categorize the current knowledge of behavioural changes in DS. The BEHAVE-AD 
(extensively reviewed in Reisberg et al., 2014) is an informant-based rating scale to assess behavioural 
disturbances that are related to AD, not including symptoms that primarily relate to functional and cognitive 
deterioration. It scores 25 behavioural symptoms in seven main symptomatic categories (Table 1) over a twoweek 
interval (Reisberg et al., 1987, 1996). Different versions of the BEHAVE-AD have been established, 
including a clinician observation-based version to reduce caregiver bias (Auer, Monteiro, & Reisberg, 1996) and 
a version adapted for institutionalized settings (De Deyn et al., 1999). 
The NPI is a validated, structured interview with a caregiver of the patient to assess the frequency and 
severity of behavioural symptoms over the past month (Cummings et al., 1994). The initial NPI evaluated ten 
types of neuropsychiatric alterations that are commonly associated with dementia (Table 1). Currently, an 
extended NPI is used that also includes night-time behaviour disturbances, and appetite and eating 
abnormalities (Cummings, 1997). Meanwhile, several other forms of the NPI have been created, including a 
nursing home version (NPI-NH) (Wood et al., 2000), a clinician-rated version (NPI-C) (de Medeiros et al., 2010) 
and a shortened form, the NPI-Q (questionnaire), for daily clinical use (Kaufer et al., 2000). Whereas the 
BEHAVE-AD is dedicated to AD, the NPI also includes behavioural symptoms that are rare in AD and more 
common in other types of dementia (Cummings, 1997). 
Strikingly, neither the BEHAVE-AD, nor the NPI, or any other behavioural assessment scales have been 
adapted and validated for AD in DS, thus not taking the DS-specific circumstances into account, such as preexisting 
behaviour and limitations associated with intellectual disability. Furthermore, not all items in these 
scales are equally valuable in DS, e.g. certain behaviour is hardly observed or relatively complex to assess in 
DS. Therefore, this review aims to take the first step towards a novel scale for BPSD in DS by summarizing and 
evaluating behavioural studies in DS and by categorizing them according to common classifications of 
behavioural and psychological symptoms (Table 1). Due to the congenital neurological alterations in DS, it is 
important to differentiate between changes that are likely related to AD and those behavioural phenotypes 
that are commonly present among the DS population regardless of AD. 
3. Diagnosis of BPSD in DS: a challenging endeavour 
Whereas the dementia field largely uses the terminology of BPSD or NPS to address behavioural and 
psychological changes, reports on demented DS subjects referred to them in numerous ways: from 
behavioural disturbances (Prasher & Filer, 1995), behavioural changes (Adams et al., 2008; Duggan, Lewis, & 
Morgan, 1996), behavioural deficits and excesses (Adams & Oliver, 2010; Adams et al., 2008; Millichap et al., 
2003) to psychiatric symptoms (Moss & Patel, 1995; Urv, Zigman, & Silverman, 2010), maladaptive behaviour 
(Cooper & Prasher, 1998; Cosgrave, Tyrrell, McCarron, Gill, & Lawlor, 1999; Urv, Zigman, & Silverman, 2008), 
challenging behaviour (Huxley, Van-Schaik, & Witts, 2005), behavioural and emotional changes (Temple & 
Konstantareas, 2005) and personality/behaviour changes (Ball, Holland, Treppner, Watson, & Huppert, 2008; 
Ball, Holland, Hon, et al., 2006; Holland, Hon, Huppert, & Stevens, 2000; Holland, Hon, Huppert, Stevens, & 
Watson, 1998), clearly indicating the lack of a consensus approach in the DS field. This diverse terminology will 
be largely referred to as BPSD in the subsequent sections. 
The diagnosis of BPSD is likely different in DS than in the general population. Such diagnoses in people 
with intellectual disabilities, including DS, are complicated by various problems (reviewed in: Bouras and Holt, 
2007). Importantly, intellectually disabled persons, and especially those with more severe disability, have an 
apparent difficulty to verbalize their emotions (Moss et al., 1993), causing the diagnosis to primarily rely on 
clinically observable behaviour and information from key informants (Moss et al., 1993; Smiley & Cooper, 
2003). For instance, understanding of relatively complex concepts, such as worthlessness or guilt, has been 
reported to require a developmental level of at least seven years of age. As such, many people with moderate 
to severe intellectual disability, including many individuals with DS, will have no, or only a scanty, notion of 
such concepts. Therefore, the diagnosis of depression, for example, cannot rely solely on patient interviews as 
feelings indicating depression may not be verbally expressed (Adams et al., 2008; Smiley & Cooper, 2003). 
Accordingly, referral is most often initiated by caregivers (Bouras & Holt, 2007). So far, the diagnosis 
of BPSD in DS has predominantly relied on informant interviews with the main caregivers and/or relatives. 
Studies based on such interviews have suggested that the behavioural presentation of AD in DS is different 
from that in the general population. In particular, BPSD appear to be more prominent than, and present prior 
to, the decline in episodic memory (Ball et al., 2008; Ball, Holland, Hon, et al., 2006; Nelson, Orme, Osann, & 
Lott, 2001). There may be several reasons for this, e.g. informants may be more sensitive to particular changes 
in behaviour and personality, especially those affecting daily care and management, as compared to cognitive 
changes. Consequently, this would lead to relative over-reporting of (certain) BPSD as compared to the 
deterioration in memory functioning (Adams et al., 2008; Holland et al., 1998). Moreover, the presence of any 
(peripheral) disorder should be carefully assessed to prevent interpretation of related behavioural changes as 
dementia (Prasher, 2009). Conversely, underreporting of symptoms is common too, e.g. due to frequent 
changes of professional caregivers, denial or misinterpretation of AD symptoms as normal ageing. Informants 
are generally able to observe the onset of certain BPSD that were not, or rarely, observed in the patient 
before, whereas it is rather hard to note mild- to moderate behavioural alterations if the specific behaviour is 
already frequently, and often variably, present. Although caregiver reports are often reliable (Jamieson-Craig, 
Scior, Chan, Fenton, & Strydom, 2010), they may sometimes be biased and confounded by various factors. As 
such, clinicians cannot always fully rely on this information (Auer et al., 1996). 
In addition, Capone, Goyal, Ares, & Lannigan (2006) stressed the complex distinction between learned 
behaviour and psychiatric symptoms in people with limited skills, such as those with DS. It is important to 
distinguish psychiatric symptomatology from the overall picture of problem behaviour, as this allows for 
specific and realistic behavioural, educational and pharmacological interventions. For instance, Fenner, Hewitt, 
& Torpy (1987) reported particularly marked inactivity and strange habits in DS, which remained relatively 
constant with age. However, this behaviour was not likely related to DS, but rather a consequence of 
prolonged hospitalization, causing such reports to be of limited value. This demonstrates the importance of 
considering the individual circumstances of the patient when evaluating BPSD, including their living situation, 
i.e. in community dwellings, assisted living facilities or larger institutionalized settings, such as nursing homes 
or hospitals. Although certain behaviour likely relates to the institutionalized environment (Fenner et al., 1987; 
Linaker & Nitter, 1990), a higher frequency of delusions, hallucinations, anxiety and aggressiveness has been 
reported in memory clinic outpatients with AD in the general population compared to their institutionalized 
counterparts (Cheng et al., 2009). This may relate to higher stress of family caregivers of community dwelling 
patients compared to care provided by professional caregivers in institutions, positive effects of specialized 
institutionalized care, and/or a higher use of psychotropic medication in institutions. In turn, BPSD are a major 
cause for early institutionalization (Finkel, 2000). 
Since no specific scale to assess BPSD in DS is yet available, particular BPSD items in DS are mainly 
assessed using certain sub-scales or domains of existing questionnaires that assess dementia in DS. The choice 
for a particular scale used in daily clinical practice is based on numerous factors, including the historical use of 
a certain questionnaire in a clinic or institute, personal preference of clinicians and caregivers, available time, 
country of origin and presence of a scale in the native language. However, the use of only one scale does not 
likely yield enough information to properly assess BPSD: certain BPSD items are extractable from individual 
dementia scales, but none of the existing ones have an all-embracing approach like the BEHAVE-AD or NPI. 
As a consequence, the limited number of BPSD studies in DS were nearly all conducted with different, 
sub-optimal scales (Table 2 and 3). Cross-sectional and longitudinal BPSD studies in the demented DS 
population are discussed in section 4, followed by section 5 that focuses on individual behavioural and 
psychological symptoms regardless of dementia (Table 4). More specifically, section 5 presents items that are 
(generally) present in a non-demented DS population, which may complicate the BPSD diagnosis, and should 
thus be cautiously considered with regard to a novel BPSD scale for AD in DS. 
Due to the relatively limited number of studies on BPSD in DS, we applied a broad, unrestricted search 
strategy to identify as many relevant papers as possible. PubMed and EBSCO Host Academic Search Premier 
databases were searched, as well as authors’ own archives of articles. Initial selection of papers was based on 
the relevance of titles and abstracts. Non-English articles, case study reports and paediatric DS studies were 
not taken into consideration in this review. 
4. BPSD studies in DS 
4.1. Cross-sectional approaches 
The first paper to report on BPSD in a series of demented DS individuals was published by Dalton and 
Crapper-McLachlan (1986). They summarized a total of 35 reported cases (63% female) that were described 
between 1946 and 1985. Neuropathological confirmation of AD was available in 33 cases. Clinical dementia 
was present in 25 individuals. Common reported features were personality changes and apathy/inactivity 
(Table 2), while depression, disorientation and hallucinations/delusions were less prevalent. 
Subsequently, Lai & Williams (1989) evaluated 96 DS subjects, of which 49 were clinically demented. 
Based on clinical observations and caregiver interviews, they reported that memory disturbances, an early sign 
of AD in the general population, were only noted in a few participants, whilst personality changes, like 
irritability and emotional lability, were primarily observed as the initial presentations of AD (Table 2). Subjects 
with more severe intellectual disability also required assistance with daily tasks and presented apathy, 
inattention and decreased social interactions as earliest signs of dementia. 
Resembling the cohort of Lai & Williams, i.e. primarily institutionalized and a minority living in 
community-based group homes, Haveman et al. (1994) studied 201 persons with DS living in institutions and 
106 in group homes. DS individuals with mild and severe disability presented more psychological problems 
with ageing. In particular, they displayed more incoherent behaviour, apathy, drowsiness, irritation, fear, 
feeling sad, lack of appetite, night-time restlessness and suspiciousness with advancing age than intellectually 
disabled individuals of another aetiology (Table 2). Taking the presence of dementia into account, the authors 
concluded that these psychological aberrations could be largely explained as primary and secondary symptoms 
of dementia, also after correcting for age, gender and the level of intellectual disability (Haveman et al., 1994). 
Using questionnaire-based caregiver interviews, Prasher & Filer (1995) studied 25 non-demented and 
15 demented DS individuals and found that demented subjects displayed significantly increased difficulties 
with activities of daily living, tiredness, day-time wandering and sleep disturbances (Table 2). Lower mood was 
also significantly more often observed among the demented group (although two participants treated for 
concurrent depressive episodes were excluded). No changes were reported for aggression, restlessness, nighttime 
wandering and eating disturbances (Prasher & Filer, 1995). 
In the subsequent years, two studies were published regarding BPSD in people with intellectual 
disabilities, of which small subgroups consisted of DS participants (Table 2). Firstly, Moss & Patel (1995) 
investigated psychiatric symptoms in 99 intellectually disabled patients: twelve demented subjects (five DS) 
were compared to 87 non-demented individuals (four DS). Informant-interviews revealed that demented 
subjects presented an increased loss of interest, irritability, slowness, and sleep difficulties, whilst depressed 
mood and delayed sleep were less common, compared to those without dementia. Deduction of DS-specific 
results was impossible due to a low number of DS subjects and data pooling of all participants. 
Similarly, Duggan et al. (1996) evaluated twelve people with mild to moderate intellectual disabilities 
and dementia, eight of which had DS. The behavioural history was assessed in relation to the duration of 
dementia, being the first paper to enlighten temporal relationships between BPSD and dementia. In contrast 
to the study of Moss and Patel, this study reported the behavioural history per subject, allowing an indicatory 
exploration of DS-specific behavioural changes in dementia. Among the DS group, multiple individuals 
presented with particular BPSD symptoms, i.e. aggression (6/8), delusions (3/8), depression (3/8) and 
hallucinations (4/8). Altered eating behaviour (3/8 DS subjects left food unswallowed in their mouths) were 
reported as well. In addition, diurnal rhythm disturbances and incontinence and misplacement of objects were 
observed, although it was not noted how many DS individuals presented this behaviour (Duggan et al., 1996). 
Two years later, a slightly more extensive study assessed behavioural and psychological symptoms in 
nineteen demented DS subjects compared to demented persons with intellectual disabilities of other 
aetiologies (on average twenty years older than those with DS). Disturbed sleep, restlessness and low mood 
were more prevalent in the DS group, whilst aggression was more frequently observed in those with a non-DS 
intellectual disability (Table 2). Even though not significant, the authors also reported increased 
uncooperativeness, auditory hallucinations and lack of energy in the DS group (Cooper & Prasher, 1998). 
Although these seven studies provide preliminary insights into BPSD in DS, a universal picture cannot 
be drawn due to various major limitations. Firstly, among the rather small number of (often institutionalized) 
participants, females were generally overrepresented. Gender may influence the prevalence of certain BPSD, 
e.g. depression is more prevalent in females, both in the general population and in DS (Cooper & Collacott, 
1994; Walker, Dosen, Buitelaar, & Janzing, 2011). Secondly, participants were relatively old (mean age >50 
years), thus likely missing early BPSD symptoms that may predict the development of AD dementia in DS. 
Thirdly, studies were retrospective and the dementia severity was not considered in the analyses, thus not 
identifying the temporal relationship between behavioural problems and the progression of dementia. 
The first longitudinal approach was undertaken by Holland and co-workers (further discussed in 
section 4.2). In their cross-sectional baseline study (Table 2), eighteen out of 75 DS subjects were diagnosed 
with dementia, of whom thirteen (72.2%) presented behaviour and personality changes. Apathy/lack of 
motivation was markedly present in ten (55.6%) of the demented individuals, compared to 15.8% in the nondemented 
group. Though no statistics were applied, apathy appeared to be more common in the demented 
subjects (Holland et al., 2000, 1998). 
In agreement, Huxley et al. (2005) found that the frequency and severity of lethargy and hyperactivity 
was significantly higher in demented than in non-demented DS subjects. Similar results, close to significance, 
were reported for irritability and stereotypy. Although the two groups differed significantly in age (Table 2), 
age was not significantly correlated with the behavioural outcome measures. Therefore, the authors 
concluded that these behavioural alterations are associated with dementia rather than normal ageing. 
Apathy was also assessed by Temple & Konstantareas (2005). They assessed BPSD in DS using the 
BEHAVE-AD (Table 1), together with the apathy subscale of the CERAD Behavioural Rating Scale for Dementia 
that compensates for the lack of a measure for apathy in the BEHAVE-AD. AD patients with DS (DS-AD, n=30, 
average age of 52 years) and without DS (AD-only, n=30, average age of 80 years) were evaluated by 
completion of both scales by a primary caregiver and by direct clinical observations during day-care 
programmes. Based on the BEHAVE-AD/CERAD scores, it was reported that the DS-AD group presented 
significantly more activity disturbances and less delusions and hallucinations. In agreement, day-care program 
observations revealed significantly increased purposeful and non-purposeful motor behaviour in DS-AD, as 
well as decreased mood (Table 2). 
Using the Behavioural and Emotional Activities Manifested in Dementia (Beam-D) scale, which is used 
for BPSD in the general population, Jozsvai (2006) assessed nineteen demented individuals with DS and 
compared his findings to those in a ‘normative’ demented population without intellectual disability (more than 
twenty years older than those with DS). Non-compliance, i.e. the extent to which subjects follow demands, 
instructions and directions from a caregiver, occurred with higher frequency and severity in the demented DS 
persons compared to the normative group (Table 2). The wilful destruction of property was rated more severe 
in the DS group as well. In contrast, insomnia was significantly more severe in the normative group. 
Deb et al. (2007) undertook a different approach, neither using clinical assessments nor established 
questionnaires, but fully relying on caregivers’ perception and description of behavioural changes that might  
be associated with development of AD in DS. The most noticeable early signs of AD were forgetfulness and 
confusion. Moreover, a general slowness was observed in various aspects of daily functioning (eating, 
speaking, walking), as well as loss of interest and motivation, social withdrawal, sleep problems and emotional 
changes (tearfulness, being upset). These observations point in the direction of activity, affective and diurnal 
rhythm disturbances in terms of BPSD categories. 
These studies did not consider prodromal stages of dementia prior to clinical dementia diagnosis. Urv 
and co-workers associated the presence of maladaptive behaviour with the status of dementia, i.e. no 
dementia, questionable dementia (which largely resembles MCI in the general population), possible dementia 
and definite dementia. The non-demented group presented the lowest frequency and severity of maladaptive 
behaviour. To reveal possible early signs of AD in DS, the groups with no dementia and questionable dementia 
were compared and it was reported that a higher number of questionable-demented subjects presented 
regressive behaviour, inattentiveness, low energy, non-assertiveness, withdrawal, destructiveness, hostility, 
impulsivity, object attachment and aggressive behaviour (Table 2). Furthermore, confused thinking and 
tiredness were significantly more common in possible-demented than in non-demented individuals. Overall, 
those with questionable, possible and definite dementia presented more physical symptoms of depression, 
e.g. low energy, than those without dementia. Finally, dependence, fearfulness, low energy, nonassertiveness, 
sadness, self-injurious behaviour, self-stimulation, sleep problems, unusual motor behaviour 
and withdrawal were most common in the definite demented group, whereas this group displayed the lowest 
prevalence of aggressiveness, attention-seeking, being overly sensitive, complaining, destructiveness, eating, 
impulsivity, overactivity, paranoia, social inadequacies and tantrums (Urv et al., 2008). 
Two years later, this cohort was re-assessed using this four-part dementia classification, now in 
relation to psychiatric symptoms. Similarly, the non-demented group presented the lowest frequency of 
psychiatric symptoms, i.e. delusions, hallucinations, behavioural disturbances and depression. Interestingly, 
the proportion of subjects presenting delusions, depressive symptoms (non-event related sadness, sleeping 
difficulties and eating disturbances) and wandering were the lowest in the non-demented group and increased 
with the status of dementia to the highest proportion in the definite dementia group. Again, to reveal early 
signs of AD in DS, the non-demented and questionable-demented groups were compared: those with 
questionable dementia were twice as likely to display paranoid ideation of things being stolen, 2.6 times more 
likely to present verbal and physical violence and showed a higher prevalence non-event related sadness, 
eating problems and sleeping difficulties. In addition, agitation/restlessness, threatening behaviour and 
wandering were most frequent in those with definite dementia (Urv et al., 2010). In agreement, Oliver and coworkers 
(2011) demonstrated that behavioural excesses (pooled scores from eleven items) and deficits 
(pooled scores from seventeen items) were significantly more common in demented DS individuals (n=12) with 
regard to their number, frequency and management (Oliver, Kalsy, Mcquillan, & Hall, 2011). In short, particular 
psychiatric symptoms seem to correlate with the status of dementia and might thus facilitate earlier diagnosis 
of AD in DS. 
Recently, we examined BPSD in relation to the status of dementia by studying demented, converted 
and non-demented DS subjects and its possible neurobiological underpinnings (Dekker et al., 2015). In a 
longitudinal clinical follow-up of 10-14 years, 151 DS participants were yearly assessed using two validated 
functional scales, i.e. the Dementia Questionnaire for persons with an intellectual disability (DMR) (Evenhuis, 
Kengen, & Eurlings, 1998) and Social Competence Rating Scale for persons with an intellectual disability (SRZ) 
(Kraijer, Kema, & de Bildt, 2004). The DMR and SRZ were not specifically developed for evaluating BPSD, but 
report on short- and long-term memory, social functioning and activities of daily living. Consequently, we 
selected questions from the scales that mapped onto a category of the BEHAVE-AD rating scale, which enabled 
us to extract four out of seven BEHAVE-AD items, i.e. paranoid and delusional ideation, affective disturbances, 
aggressiveness and diurnal rhythm disturbances. Based on certain questions from the DMR and SRZ, we 
reported that diurnal rhythm disturbances, apathy and aggressiveness were significantly more frequent in the 
demented group compared to the converted and non-demented subjects (Dekker et al., 2015). 
Taken together, mounting evidence suggests that particular BPSD are generally more prevalent in DS 
individuals diagnosed with dementia compared to those without. Only Cosgrave et al. (1999) reported no 
increased prevalence of behavioural disturbances in demented DS individuals. More than a dozen crosssectional 
studies have been published using a variety of measures for dementia symptoms, but none took a 
comprehensive approach to assess all BPSD items in DS. This is likely related to the use of various, quite 
diverse, suboptimal scales from which particular BPSD items were extracted. The lack of a validated BPSD scale 
for DS, like the BEHAVE-AD and NPI in the general AD population, together with the relatively limited group 
sizes do not enable reasonable inter-study comparisons. Comparisons with diverse control groups were used: 
from non-demented persons with DS or individuals with intellectual disabilities of other aetiologies to AD 
patients in the general population. Finally, a temporal relationship between BPSD and the onset and 
progression of dementia cannot be established from these cross-sectional approaches, pointing at the great 
exigency for longitudinal approaches. 
4.2. Longitudinal approaches 
In DS individuals, AD-like neuropathology is extensively present from 40 years of age. The onset of 
clinical dementia symptoms, however, tremendously varies in time. Hence, a cross-sectional study design 
including clinically demented and non-demented DS groups is rather restrictive: progressive neurobiological 
changes in the DS brain likely affect behaviour already long before memory decline is observed (Dekker et al., 
2015). In addition, the previously discussed studies primarily comprised elderly cohorts (mean age of 50 years 
and older), therefore likely presenting extensive AD-like neuropathology. Accordingly, early BPSD that 
correlate with the advancing neuropathology are likely missed, pointing at the need for longitudinal 
assessments that start at a younger age. Table 3 enlists longitudinal studies that (partially) assessed BPSD in 
DS. 
To our knowledge, Evenhuis (1990) initiated the first longitudinal approach. The clinical course of 
dementia was prospectively assessed for seventeen middle-aged DS individuals. Standardized diagnostic 
procedures for dementia in DS were not available at the time, and the author relied on careful sequential 
clinical observations, medical examinations, history taking, and, if institutionalized, interviews with nurses at 
least twice a year. Fourteen out of seventeen subjects developed dementia that was neuropathologically 
confirmed as AD. Interestingly, apathy and withdrawal, as well as daytime sleepiness, were markedly reported 
in the first year of dementia, which was the first indication of (relatively) early signs of dementia in DS 
(Evenhuis, 1990). 
In the same decade, Visser et al. (1997) followed 307 institutionalized DS subjects for five to ten years 
to assess dementia and other clinical symptoms. Using a self-developed Early Signs of Dementia Checklist, 
decreased interest, motivation and general pace, as well as mood changes and exaggeration of personality 
traits, were found among the first signs of deterioration. With the onset of distinctive dementia (56 subjects 
developed dementia), these signs increased in prevalence. Furthermore, temporal and spatial disorientation, 
nocturnal anxiety and reversal of diurnal rhythm were more pronounced in demented individuals. Aware of 
the institutionalized setting, this study suggested, again, that apathy is an early dementia symptom in DS. 
A more encompassing longitudinal study was undertaken by Holland and co-workers (Table 3). 
Changes in four domains, i.e. personality/behaviour, memory, daily living skills and general mental functioning, 
were assessed at baseline (n=75 DS) and re-assessed after clinical follow-ups of eighteen months (n=68) and 
five years (n=55). Interestingly, the first and primary alterations over the first eighteen months concerned 
BPSD rather than memory. Indeed, in the age groups of 30-39 and 40-49 years of age, 29.2% and 31% 
(respectively) presented changes in personality, without changes in memory and/or the other two domains. In 
retrospect, relatives and caregivers particularly noted changes in apathy and stubbornness, which are more 
typical frontal lobe symptoms. Therefore, the authors suggested that such frontal lobe-related changes in 
behaviour and personality, rather than cognitive decline, might be the earliest sign of AD in DS and, as such, 
predict the onset of AD (Holland et al., 2000, 1998). 
In continuation, 55 participants from this cohort were followed for five years, specifically assessing 
early BPSD in relation to diagnostic criteria for frontotemporal dementia (FTD) (Ball, Holland, Hon, et al., 2006). 
Four DS subjects had AD at baseline, another six developed AD over the course of five years. Importantly, 
among these six converters, four met criteria for FTD at baseline. Ball and co-workers reported that meeting 
the FTD criteria conveyed at least a 1.5 times higher chance to develop AD over five years. Furthermore, the 
presence of at least one change in behaviour and personality (not yet sufficient to establish the FTD diagnosis) 
yielded at least a 1.5 times higher risk to develop FTD-like symptoms, memory changes or AD over the course 
of five years in DS subjects that had no memory changes or dementia at baseline. In other words, altered 
behaviour and personality appeared to be an early and predictive sign of AD in DS. Interestingly, whereas MCI 
is known to convey a strongly elevated risk to develop AD in the general population (Jessen et al., 2014), 
memory changes in DS individuals did not significantly increase the odds to convert to AD over the five year 
period (Ball, Holland, Hon, et al., 2006). The authors therefore suggested that AD in DS is initially revealed as 
frontal lobe-associated behaviour and personality changes without prominent functional memory decline. 
Conversely, Adams & Oliver (2010) reported an increased frequency of BPSD only in DS individuals 
with cognitive deterioration. They followed thirty DS individuals for a period of sixteen months. Based on the 
Neuropsychological Assessment of Dementia in Individuals with Intellectual Disabilities test battery, ten 
individuals were identified with early cognitive deterioration over this period. Only in those with cognitive 
deterioration, a significantly increased frequency of behavioural excesses and deficits (not specified) was 
observed. In agreement, other (cross-sectional) studies previously reported deteriorated episodic memory 
prior to the full clinical diagnosis of AD in DS (Deb et al., 2007; Devenny et al., 2000; Devenny, Zimmerli, Kittler, 
& Krinsky-McHale, 2002; Krinsky-McHale, Devenny, & Silverman, 2002). Caregivers of demented DS subjects 
described confusion and general forgetfulness with a particular loss of recent memories and relative spared 
distant memory as the most prominent early sign of dementia in DS (Deb et al., 2007). Depending on the 
particular tests and the study population, it might therefore be more likely that changes in behaviour and 
personality do not only precede, but are also accompanied by cognitive decline prior to the AD diagnosis. 
In addition, the FTD diagnosis of DS subjects should be attenuated. FTD is clinically manifested in two 
subtypes: primary progressive aphasia and the behavioural variant of frontotemporal dementia (bvFTD). 
Indeed, the bvFTD comprises severe behaviour and personality changes, including apathy, disinhibition, 
executive dysfunction, loss of empathy or stereotypic behaviour, with relative preservation of memory (Sieben 
et al., 2012). Differential diagnosis between bvFTD and AD, specifically the frontal variant of AD with 
prominent behavioural aberrations and executive dysfunction, is fairly difficult when solely based on clinical 
data (Woodward et al., 2010). Ball and co-workers utilized the rather broad clinical criteria of the FTD checklist 
by Gregory and Hodges (1993). However, the neuropathology underlying FTD is different from AD, and to the 
best of our knowledge, FTD-positive neuroimaging or neuropathology in demented DS subjects has not been 
demonstrated so far. Therefore, the reported cases of FTD in DS are most probably cases of AD with prominent 
frontal features (frontal variant), which would be most in line with the AD-like neuropathology in DS. Instead 
of FTD, or FTD-like symptoms, we will thus refer to frontal lobe symptoms in the remainder of this review. 
To more extensively assess the hypothesized frontal lobe dysfunction, executive function (generally 
associated with frontal lobe integrity) was studied in 122 DS subjects, including the aforementioned 55 
subjects (Ball et al., 2008). Again, a substantial percentage of non-demented participants (60.3%) presented 
one or more changes in behaviour/personality, of which a subgroup (29.8%) also showed memory changes. 
Particularly marked were reduced empathy (43.6%), emotional lability (35.9%), social withdrawal (21.8%), 
distractibility (16.7%), perseveration/verbal stereotypes/echolalia (16.7%), disinhibition (14.1%), impulsivity 
(14.1%) and apathy (14.1%). Notably, the number of informant-reported BPSD in the non-demented DS group 
significantly predicted the performance on two (frontal-lobe associated) executive function tasks (Tower of 
London, scrambled boxes), which supported the authors’ hypothesis that behaviour/personality alterations 
and executive dysfunction, associated with frontal lobe dysfunction, are early signs of AD in DS (Ball et al., 
2008). 
Supportive evidence of this hypothesis was generated by two other studies. In a cross-sectional 
approach, Deb et al. (2007) reported the early presence of marked forgetfulness, as well as frontal loberelated 
symptoms, i.e. lack of interest and motivation, social withdrawal, depressive symptoms and general 
pervasive slowness (section 4, Table 2). Secondly, Nelson and co-workers, showed that individuals with 
abnormal physical findings at baseline (atrophy and ventricular enlargement on MRI and pathological reflexes 
during neurological examination) scored significantly lower on cognitive functioning, including memory 
(indicative of probable dementia), and higher on indifference and depression, both at baseline and after 
follow-up of one year. Indeed, indifference and depression are associated with prefrontal lobe dysfunction 
(Nelson et al., 2001). 
Despite the various indications in favour of an early frontal lobe dysfunction hypothesis in DS, these 
frontal lobe symptoms may not be as informative as has been suggested. Recently, we found that at least one 
frontal lobe symptom of the Middelheim Frontality Scale, which discriminates between AD and FTD (De Deyn 
et al., 2005a), was displayed in 84% of the MCI patients and 97% of the AD patients in the general population, 
but also in 50% of the control group (Van der Mussele et al., 2013b). Therefore, it is essential not to 
overestimate the importance of frontal lobe symptoms and continue investigating the full range of BPSD in DS. 
Urv et al. (2008), for instance, compared maladaptive behaviour in non-demented DS individuals that 
remained non-demented to those that converted to questionable dementia (largely resembling MCI), thus 
pointing at early dementia symptoms (Table 3). A range of BPSD items, not only frontal lobe symptoms, were 
significantly more prevalent in the converters: confused thinking, dependence, fearfulness, object attachment, 
regressive behaviour, sadness and social inadequacies (Urv et al., 2008). 
In summary, not more than a mere handful of studies longitudinally assessed BPSD in DS. Although 
these studies provided the first insights into the relationship between BPSD and dementia in DS, new 
prospective studies are needed to further elucidate the temporal relationship. It is especially worth 
considering which subjects constitute the control group. After all, non-demented DS subjects of 40 years and 
older do not have clinical dementia symptoms but are in neuropathological terms AD-positive. Furthermore, 
the suggestion that frontal lobe symptoms are an early indicator of AD is of great interest, but it should be 
taken into account that these results were obtained in a relatively small cohort that presumably had 
established AD-like neuropathology. Therefore, future investigations should also include younger DS adults 
and assess the multitude of BPSD rather than only frontal lobe-associated behaviour and personality changes. 
5. Behavioural and psychological phenotypes in DS 
Since Langdon Down’s ‘Observations on an Ethnic Classification of Idiots’ (1866) and Mitchell’s notes 
on sixty-two cases of ‘kalmuc idiots’ (1876), clinicians and researchers have tried to describe and define a 
typical behavioural phenotype of DS (Collacott, Cooper, Branford, & McGrother, 1998; Down, 1866; Fraser & 
Mitchell, 1876). Is there indeed a characteristic behavioural phenotype of DS, and if so, which recurrent 
symptoms are generally present? Such pre-morbid symptoms are particularly relevant to take into account 
when assessing BPSD in DS. After all, the onset of a particular BPSD that was not, or hardly, observed in the 
patient is more likely noticed than alterations in frequency and/or severity of behaviour that was already 
commonly, and presumably also variably, present. To understand behavioural and psychological changes in DS, 
it is thus essential to evaluate behaviour not only during, but also (long) before the onset of the clinical 
dementia symptoms. Section 5 discusses such behavioural and psychological changes in DS regardless of 
dementia. 
One of the first comprehensive studies to examine a behavioural phenotype in DS adults was 
published by Collacott et al. (1998). In a large, population-based study, thirteen maladaptive behaviours were 
assessed in 360 adults with DS and 1829 adults with intellectual disabilities of other aetiologies (Table 4). 
Absconsion, aggression, antisocial behaviour, attention-seeking, excessive activity, making excessive noise, 
disturbing others at night, property destruction, scattering objects, self-injury, and untruthfulness were 
significantly less prevalent in DS individuals compared to those with intellectual disabilities of other 
aetiologies, pointing at a specific behavioural phenotype of DS. Regarding the early presence of AD 
neuropathology in DS, the study population was subsequently subdivided into a group younger than 35 years 
of age and a group of 35 years and older. No significant differences were revealed between both groups, likely 
due to the fact that behaviour was scored on a dichotomous scale (present/absent) (Collacott et al., 1998). For 
instance, behaviour that increased from ‘sometimes’ to ‘often’ would be rated similarly using such a binominal  
scoring, thus omitting any information about severity and frequency. 
Similarly, Straccia, Baggio & Barisnikov (2014) compared 34 non-demented DS subjects to 34 
intellectually disabled persons of other aetiology. The DS group scored significantly lower on mental illnesses, 
especially on subscales for avoidant disorder, psychosis and behavioural signs of depression. In addition, lower 
scores for behavioural problems were reported in the DS group, in particular for aggressive/disruptive, selfabsorbed 
and depressive behaviour. Conversely, the DS group scored significantly higher on general social 
behaviour, social attitude, socio-emotional behaviour and respect of social rules. 
Compared to the general population, however, a higher prevalence of behavioural disturbances 
seems to be present in DS. Indeed, it has been estimated that psychiatric co-morbidity is prevalent in 18-38% 
of the DS children, which is greater than in the general population, but probably lower than in other 
intellectual disabilities (Capone et al., 2006). Problem behaviour was also more commonly reported in late 
adolescents with DS than in those without DS (van Gameren-Oosterom et al., 2013). Higher scores, indicating 
more problem behaviour, were observed in those with more severe intellectual disability. The largest 
differences were observed for withdrawal, somatic complaints, social problems, attention problems and 
thought problems. Compared to typical behaviour in DS children (not further discussed in this article and 
reviewed by Capone et al. (2006), Dykens (2007), Visootsak and Sherman (2007)), a decrease in externalizing 
behaviour (aggression, inattention, hyperactivity, opposition) and an increase in internalizing behaviour 
(withdrawal, shyness, depression) has been observed with ageing to adolescence and adulthood (Capone et 
al., 2006; Dykens, 2007; van Gameren-Oosterom et al., 2013; Visootsak & Sherman, 2007). However, in a 
cross-sectional (n=25) and a longitudinal (n=28) cohort of non-demented adults with DS, no significant 
associations were reported between age and the number and severity of behavioural and emotional problems, 
taking gender, medical co-morbidities and the level of intellectual disability into account as covariates (Makary 
et al., 2014). 
Despite the use of a large variety of (sub-optimal) scales and diverging study results, particular 
behaviours appear to be more prevalent in DS than in the general population. In addition to the previously 
discussed cross-sectional (Table 2) and longitudinal dementia studies (Table 3), section 5 describes behavioural 
and psychological changes in DS regardless of dementia, classified according to the items of the BEHAVE-AD 
(Table 1). Section 5 very briefly recapitulates the results from the dementia studies, followed by a discussion of 
studies that did not consider dementia in DS (Table 4), which is important for establishing whether particular 
behaviour is omnipresent in adult DS individuals or whether the that behaviour primarily relates to the onset 
and progression of dementia. In summary, Figure 1 depicts the temporal relationship between BPSD and the 
clinical diagnosis of AD. Cautious interpretation is required, however, as longitudinal studies assessing the 
temporal relationship between BPSD and the status of dementia are largely lacking. 
5.1. Activity disturbances 
Activity disturbances are among the most common and relatively persistent BPSD in the general AD 
population, with a reported point prevalence up to 58% (Cheng et al., 2009; Eustace et al., 2002). Mounting 
evidence suggests that activity disturbances are also significantly more prevalent in demented DS subjects 
than in AD patients without DS (Temple & Konstantareas, 2005) or demented individuals with intellectual 
disability of another aetiology (Cooper & Prasher, 1998). In addition, Huxley et al. (2005) found an increased 
frequency and severity of hyperactive behaviour in DS individuals with (early) dementia, compared to a nondemented 
DS group. Conversely, a study based on caregivers’ reports revealed that a general slowness of daily 
functioning was markedly noted in demented DS individuals (Deb et al., 2007), which corresponds to the 
observations of Moss & Patel (1995) in a group of demented intellectually disabled persons. 
Whilst such inconsistent results have been reported in the demented DS population, those without 
clinical dementia symptoms provide a more clear-cut picture. As discussed above, a decrease in externalizing 
behaviour, including hyperactivity, has been associated with ageing in DS. Relatively high scores of 
hyperactivity/attention problems were found in DS children with a reported prevalence of ADHD up to 43.9% 
(Ekstein, Glick, Weill, Kay, & Berger, 2011), as well as in adolescents with DS, and this strongly decreased 
towards adulthood (Capone et al., 2006; Dykens, 2007; van Gameren-Oosterom et al., 2013). Indeed, 
significantly less excessive activity was reported in DS than in intellectual disabilities of other aetiologies 
(Collacott et al., 1998). Charlot, Fox & Friedlander (2002) reported (obsessional) slowness in eleven DS adults 
of 21-45 years of age. Furthermore, reduced activity may relate to the high prevalence of obesity that has 
been reported in the DS population (Melville, Cooper, McGrother, Thorp, & Collacott, 2005; Prasher, 1995b; 
Rubin, Rimmer, Chicoine, Braddock, & McGuire, 1998). 
In sum, hyperactivity in DS probably diminishes with increasing age. The onset of dementia in DS 
seems to be marked by either a general slowness or by excessive activity. It is speculative whether this relates 
to different subpopulations or a different status of dementia, and should be investigated further. 
Nevertheless, activity disturbances are generally easy to observe for non-clinicians and are thus likely to be 
noted as BPSD by caregivers and relatives. Elucidating the progression of activity disturbances in relation to 
dementia in DS is of essence as detection of activity alterations may constitute a clearly observable indication 
for referral. 
5.2. Affective disturbances 
The relationship between apathy and depression is complex and it has long been disputed whether 
apathy should be considered as a separate neuropsychiatric item. Although apathy is clearly related to 
depression, nearly half of the AD patients presenting apathy do not have major depression, i.e. loss of interest 
is more common than depressed mood, thus settling this controversy in favour of apathy as a separate item 
(Landes, Sperry, & Strauss, 2005; Mortby, Maercker, & Forstmeier, 2012; Tagariello, Girardi, & Amore, 2009). 
Apathy is generally defined as a loss of motivation and is, among other symptoms, particularly 
manifested by diminished interest, indifference, and blunted emotional responses. Besides the commonalities 
between apathy and depression, depression also comprises guilt, pessimism and self-criticism, such as feelings 
of worthlessness (Landes et al., 2005; Marin, 1996; Tagariello et al., 2009). Nevertheless, the overlap between 
apathy and depression, together with the use of different definitions and scales, cause large variation in the 
prevalence reports of apathy in the AD population (Tagariello et al., 2009). Indeed, apathy is often 
misdiagnosed as depression, even if signs of dysphoria or depressed mood are absent (Mortby et al., 2012). 
For effective treatment, however, careful identification of the symptoms is required to accurately 
distinguish between apathy and depression. It has been suggested that feelings of worthlessness, for instance, 
could be helpful for the differential diagnosis (Tagariello et al., 2009). As previously discussed, DS individuals 
have marked difficulty to express their feelings, thus complicating the differential diagnosis. Taking this into 
account, the hereafter discussed studies into apathy and depression in DS should be cautiously interpreted. 
5.2.1. Apathy and isolation 
Apathy is the most common BPSD in the general AD population with a reported prevalence up to 77% 
(Mega, Cummings, Fiorello, & Gornbein, 1996; Mitchell, Herrmann, & Lanctôt, 2011). An increasing body of 
evidence also suggests that apathy is common in demented DS individuals (Deb et al., 2007; Dekker et al., 
2015; Evenhuis, 1990; Haveman et al., 1994; Holland et al., 2000, 1998; Lai & Williams, 1989; Moss & Patel, 
1995; Nelson et al., 2001; Oliver & Holland, 1986; Visser et al., 1997). However, apathy is frequently observed 
in non-demented DS subjects as well. In a relatively young group of hospitalized DS subjects, Fenner et al. 
(1987) reported withdrawal and inactivity, both associated with apathy, in respectively 18% and 39% of the 
individuals (Table 4), although this high prevalence is likely due to their hospitalization. Next, in a cohort of 529 
individuals with intellectual disability (202 DS), it was found that withdrawal and emotional instability (e.g. 
mood changes) coincided with significant regression in adaptive behaviour (Urv, Zigman, & Silverman, 2003). 
Furthermore, in two population-based samples (Table 2 and 3) apathy was reported in resp. 18% and 
14.1% and social withdrawal in 16% and 21.8% of the non-demented DS individuals (Ball et al., 2008; Ball, 
Holland, Hon, et al., 2006). In continuation, Ball et al. more extensively studied apathetic features in relation to 
their hypothesis of frontal lobe-associated alterations as early sign of AD in DS. Based on informant interviews 
with the main caregiver of 78 non-demented DS adults, 47 non-demented individuals exhibited one or more 
frontal-lobe symptoms. Among those 47 subjects, 27 (57.4%) presented apathetic features (Ball, Holland, 
Watson, & Huppert, 2010). Similarly, Ghezzo and co-workers (2014) reported increased loss of interest, social 
isolation in non-demented DS individuals over forty years of age, which likely relates to the AD-like 
neuropathology that is present at that age. Therefore, apathy is apparently omnipresent and, as such, an 
important (early) BPSD item to identify in DS. 
This is particularly relevant as apathetic individuals generally show impairment in daily living skills, 
and apathy, as such, could lead to activity disturbances. Indeed, increased fatigue in daily tasks was reported in 
older, non-demented DS adults (Ghezzo et al., 2014). The lack of identification of apathetic behaviour might 
cause caregivers to misinterpret the symptoms as deliberate opposition or laziness (Landes et al., 2005). 
Indeed, caregivers of demented DS subjects noted a pronounced lack of interest and motivation and related 
behaviour, and reported this as laziness (Deb et al., 2007). Together with the lack of accurate differential 
diagnosis in various studies, this demonstrates the need for a novel BPSD scale in DS, which should include 
clear measures to distinguish between apathy and depression. 
5.2.2. Depression 
The abovementioned studies (section 4, Tables 2 and 3) suggested that demented DS subjects have an 
increased prevalence of low mood (Cooper & Prasher, 1998; Nelson et al., 2001; Prasher & Filer, 1995; Temple 
& Konstantareas, 2005). The association between dementia and depression was confirmed in 61 persons with 
DS: all DS subjects with functional decline were depressed, and 43% of the depressed DS subjects had 
functional decline compared to none of the depressed individuals with intellectual disabilities of other 
aetiologies (Burt, Loveland, & Lewis, 1992). Specifically, depressive symptomatology associated with dementia 
in DS included depressed mood, reduced appetite, weight loss, slowing and disturbed sleep patterns (Prasher, 
1995a). Furthermore, in a longitudinal study of 506 DS individuals, Coppus et al. (2006) reported a significant 
association between a history of depression and dementia. Those subjects with both dementia and depression 
were closely followed up to ensure that depression was not misdiagnosed as dementia, yielding an overall 
prevalence of depression of 22.7%. 
Interestingly, a fourteen year longitudinal dementia follow-up in 77 female DS participants was 
recently published: depression was not significantly more prevalent in clinically demented subjects compared 
those without dementia. Indeed, in the most recent clinical assessment, including a psychiatrist report on 
depression, 49.3% of the demented subjects and 50% of the non-demented presented depression, although 
only eight subjects were still non-demented after fourteen years (McCarron, McCallion, Reilly, & Mulryan, 
2014). 
Irrespective of dementia, however, a particular vulnerability for depression has been suggested in 
adult DS individuals, which might obfuscate the relationship between depression and AD. Myers & Pueschel 
(1991) reported a prevalence of 6.1% in 164 non-demented DS subjects over 20 years of age, but observed no 
depression in 261 DS individuals below 20 years of age. Others reported a three times higher number of 
depressed DS individuals (11.3%) compared to aged-matched controls with intellectual disability not due to DS 
(4.3%, Collacott et al., 1992). Later, Prasher & Hall (1996) found 5% as point prevalence of depression in DS. 
Nonetheless, Mantry et al. (2008) did not confirm this and demonstrated that depression in DS was even less 
common than in other intellectual disabilities, although statistical analysis were not performed due to a rather 
low number of subjects. 
The prevalence of depression in adult DS individuals thus ranges between 5% and 50%, depending on 
diagnostic criteria, screening methodology (clinical observations, informant interviews etc.) and the particular 
study cohort. With a global point prevalence of major depressive disorder of 4.7% in the general population 
(Ferrari et al., 2013), depression is likely more common in DS. This higher prevalence might correspond to the 
increased co-morbid depression in MCI (16%) and AD (25%) in the general population (Van der Mussele et al., 
2013a). Indeed, depression and dementia share various common symptoms, and depression can negatively, 
though reversibly, influence cognition and daily functioning. Therefore, depression might be misdiagnosed as 
dementia, pointing at the importance of careful differential diagnoses (Burt et al., 1992; Meins, 1995; Prasher, 
2009). Whether the increased prevalence in DS relates to the early presence of neuropathological hallmarks of 
AD remains to be elucidated. Although the presence of depression, as such, may not be a predictive item for 
AD, (early) identification of depressive symptoms in DS is of utmost importance to enable therapeutic 
interventions, which may contribute to improvement of the quality of life. 
5.3. Agitation and aggressiveness 
Agitation and aggression occur in up to 60% of the AD patients in the general population, and this 
prevalence is affected by the residential situation, with a higher frequency in nursing homes (C. Ballard & 
Corbett, 2013; Cheng et al., 2009; Eustace et al., 2002; Mega et al., 1996). Among the demented DS 
population, a relatively high prevalence of agitated symptoms such as irritability and uncooperativeness has 
been suggested (Cooper & Prasher, 1998; Dalton & Crapper-McLachlan, 1986; Lai & Williams, 1989; Moss & 
Patel, 1995; Temple & Konstantareas, 2005). Indeed, Urv and co-workers (2010) reported agitation in 43.3% of 
the DS subjects with definite dementia, compared to 16.7% in those without. 
In addition, increased aggression has been found in demented DS individuals (Dekker et al., 2015; 
Duggan et al., 1996; Urv et al., 2008, 2010). However, Cosgrave et al. (1999) showed that the presence of 
dementia is not predictive of aggression in DS. Indeed, others found no increased prevalence of aggression in 
demented DS subjects in comparison with non-demented DS individuals (Prasher & Filer, 1995) or with AD 
patients in the general population (Temple & Konstantareas, 2005). Cooper and Prasher (1998) even reported 
less aggression in a demented DS group than in demented individuals with intellectual disability of another 
aetiology. 
The latter corresponds to the reduced prevalence of aggression found in the DS population, when 
dementia is not considered. Two large population-based studies showed that aggression was more than three 
times less likely to be present in DS subjects compared to individuals with intellectual disabilities related to 
other aetiologies (Collacott et al., 1998; Tyrer et al., 2006). Similarly, aggressive behaviour was independently 
associated with not having DS (Cooper et al., 2009). None of these three large scale studies reported the 
presence of clinical dementia symptoms, even though one attempted to take this into account by arbitrarily 
subdividing the cohort into two age groups (<35 and ≥35 years) and demonstrating a rather similar low 
prevalence of aggression in both groups. 
Taken together, aggression is likely less present in the (non-demented) DS population. Agitation 
appears to be more prevalent in demented than in non-demented persons with DS. However, cross-sectional 
assessment of aggressive behaviour in demented DS cohorts yielded inconsistent results. This points at the 
necessity for longitudinal follow-up of DS individuals to establish a temporal relationship between 
agitation/aggression (frequency, severity) and the onset and progression of clinical dementia. 
5.4. Anxieties/phobias 
Up to half of the general AD population displays anxiety and phobias (Cheng et al., 2009; Eustace et 
al., 2002; Mega et al., 1996). Due to the fact that anxiety and phobias have hardly been investigated in DS, 
much remains unknown. In the few DS studies that did include this BPSD, no consistent prevalence data were 
reported. The only study comprehensively looking at anxiety and phobias in relation to AD demonstrated no 
significant difference in prevalence between AD patients with and without DS (Table 2; Temple & 
Konstantareas, 2005). 
In the non-demented DS population, anxiety and phobias are less common. It is generally thought 
that with increasing age, externalizing behaviour decreases and internalizing behaviour, including anxiety, 
increases in DS (Visootsak & Sherman, 2007). However, in a DS group younger than 20 years, phobias were 
present in 1.5% of the cases, whilst in the group aged 20 years and older this decreased to 0.6% (Myers & 
Pueschel, 1991). A similarly low prevalence (1.5–2.7%) was reported by Mantry et al. (2008). Others 
longitudinally followed 52 DS subjects from childhood to adulthood (mean adult age: 26.6 years) and found 
that 10% showed phobic anxiety (McCarthy & Boyd, 2001). Adolescents and young adults with DS were also 
investigated by Capone and co-workers who reported significantly higher anxiety scores in DS subjects with 
major depression than in those without behavioural concerns (Capone et al., 2006). Finally, the use of a joint 
subscale for anxiety and depression revealed a significantly lower prevalence of anxious/depressive problems 
in late adolescents with DS compared to those without DS (van Gameren-Oosterom et al., 2013). 
5.5. Diurnal rhythm disturbances and sleep disorders 
In up to 40% of the AD patients in the general population, marked sleep disturbances have been 
reported (Moran et al., 2005; Shin et al., 2014). Similarly, an increased prevalence of sleep problems was found 
in the demented DS population (Cooper & Prasher, 1998; Deb et al., 2007; Dekker et al., 2015; Moss & Patel, 
1995; Prasher & Filer, 1995; Temple & Konstantareas, 2005). 
Among the non-demented DS population, a number of studies have demonstrated a high prevalence 
of sleep disturbances in children and adolescents with DS, including obstructive sleep apnoea (OSA), sleepdisordered 
breathing, bedtime resistance, sleep anxiety, daytime sleepiness, parasomnias and night waking 
(Breslin, Edgin, Bootzin, Goodwin, & Nadel, 2011; Carter, McCaughey, Annaz, & Hill, 2009; Chen, Spanò, & 
Edgin, 2013; de Miguel-Díez, Villa-Asensi, & Alvarez-Sala, 2003; Marcus, Keens, Bautista, von Pechmann, & 
Ward, 1991; McDowell & Craven, 2011). Reports on the altered sleep in DS adults, however, are scarce. In a 
rather small, not-population-based cohort of adult DS individuals, Trois et al. (2009) found an increased 
prevalence and severity of OSA in DS adults than in non-DS controls. Obstructive sleep apnoea syndrome, 
including sleep fragmentation, OSA, hypoventilation and hypoxemia was frequently observed. Strikingly, 
abnormal polysomnograms were observed in 94% of the DS adults. These sleep disturbances likely relate to 
the (developmental) anatomical abnormalities, general hypotonia and increased risk for obesity in DS (Trois et 
al., 2009). 
Although these sleep disorders are not directly caused by dementia, they are very important to 
consider as they may aggravate cognitive decline. For instance, OSA in the general population is associated 
with increased cognitive impairment (Lal, Strange, & Bachman, 2012; Yaffe et al., 2011), and has been 
suggested to lead to prefrontal cortical dysfunction and subsequent executive dysfunction (Beebe & Gozal, 
2002). Only recently, it has been argued that the relationship between poor sleep and cognitive decline is very 
worthwhile to investigate in DS (Fernandez & Edgin, 2013), but so far only a few efforts have been undertaken. 
Chen and co-workers (2013) found that increased OSA related to greater executive dysfunction (verbal fluency, 
inhibition) in older adolescents and younger adults with DS. Executive functioning is strongly associated with 
the prefrontal cortex and, as such, OSA may negatively affect this area. Consequently, the authors 
hypothesized that this early sleep disruption might advance dementia symptoms or enhance decline (Chen et 
al., 2013). Indeed, this would be in concordance with the previously discussed frontal lobe-associated BPSD, 
which were found as relatively early signs of AD in DS. Furthermore, obstructive sleep apnoea syndrome was 
significantly more present in adolescents and younger adults with DS and a diagnosis of major depressive 
episode, compared to those without depressive symptoms, suggesting that OSA might be a common comorbidity 
of depression in DS (Capone, Aidikoff, Taylor, & Rykiel, 2013). 
In summary, sleep disturbances are omnipresent in the demented and non-demented DS population. 
Irrespective of its cause, sleep disorders have been described to significantly correlate with cognitive 
functioning and BPSD, such as apathy/indifference, depression and aggressiveness in the general population 
(Shin et al., 2014). As such, poor sleep probably aggravates cognitive decline and BPSD in DS as well. Due to the 
fact that non-demented DS subjects have a high risk to display sleep problems, the presence of sleep disorders 
does not likely differentiate between those with and without dementia. Therefore, longitudinal sleep studies 
are highly required to establish the change of sleep patterns, e.g. increased frequency or severity of OSA, in 
relation to the onset and progress of dementia in DS. 
5.6. Psychosis, hallucinations, paranoia and delusions 
Psychotic symptoms, such as hallucinations and paranoid/delusional ideation have been reported in 
up to 45% of the non-DS AD patients – delusions being generally more common than hallucinations (Eustace et 
al., 2002; Gauthier et al., 2010; Mega et al., 1996; Van der Mussele, Mariën, et al., 2014b). Using the BEHAVEAD, 
Temple & Konstantareas (2005) studied BPSD in AD patients with DS (DS-AD) and without (AD-only). 
Delusions (AD-only: 80%, DS-AD: 43%) and hallucinations (AD-only: 53%, DS-AD: 23%) were relatively common 
and significantly lower in the DS-AD subjects (Table 2). Clustering the scores of delusions and hallucinations 
into one category of psychotic behaviour, and correcting for the severity of dementia, revealed that DS-AD 
individuals presented significantly less psychotic behaviour. Two other studies reported that delusions were 
present in resp. 37.5% and 58.3% and hallucinations in resp. 50% and 20.8% of the demented DS subjects 
(Duggan et al., 1996; Urv et al., 2010), which is significantly higher than in non-demented DS individuals. 
However, among those without dementia, delusions and hallucinations are not negligible. Urv et al. 
(2010) described that delusions and hallucinations were displayed in resp. 19.6% and 4.7% of the nondemented 
DS individuals. Moreover, it has been reported that not-otherwise-specified psychosis, including 
psychosis without depressive components, was present in 42% of a cohort of DS adolescents and young adults 
and the psychotic individuals were more apt to present visual and auditory hallucinations (Dykens, 2007). 
Conversely, three other studies reported no, or hardly any, psychotic behaviour in their adult DS cohorts 
(Haveman et al., 1994; Mantry et al., 2008; McCarthy & Boyd, 2001). Besides these studies and incidental case 
reports, psychotic behaviour has not been extensively studied yet. Even though psychotic behaviour is likely 
associated with dementia in DS, much remains unclear. Therefore, further research is required to establish its 
prevalence in non-demented DS individuals and how this may change over time in relation to the onset of 
dementia. 
5.7. Appetite and eating abnormalities 
Altered eating behaviour is commonly observed in AD, including altered food intake, changing 
preferences and consumption of substances that are normally not eaten (pica) (Morris, Hope, & Fairburn, 
1989). Although such behaviour causes great pressure on caregivers, changes in eating behaviour in the 
context of AD in DS have not received much attention so far. To our knowledge, only Duggan et al. (1996) 
published a more detailed report, including individual eating alterations amongst eight demented DS subjects. 
Most notably were three cases that left food unswallowed in their mouths, which was observed later in the 
course of dementia, and two subjects displaying pica – eating paper, table cloths or tampons for example. Only 
one DS individual did not show any changes in weight or eating behaviour, thus suggesting that eating 
behaviour is affected by dementia in DS (Duggan et al., 1996). Indeed, in a non-demented cohort of 186 DS 
individuals, no eating disorders or pica were observed (Mantry et al., 2008). 
5.8. Disinhibition 
Disinhibition is a frontal lobe symptom that was found to be present in up to 45% of the AD patients 
in the general population and is generally more prevalent in FTD (Cummings, 1997; De Deyn et al., 2005a; 
Mega et al., 1996; Van der Mussele et al., 2013b). In DS, disinhibition is not comprehensively assessed and 
different studies reported on different features related to disinhibition – from impulsivity and reduced 
empathy to unacceptable habits – making comparisons rather hard. For instance, Urv et al. (2008) found more 
impulsivity in DS individuals with questionable dementia compared to their non-demented counterparts, 
suggesting that it might be an early symptom of AD in DS. Similarly, disinhibition features, including 
distractibility, disinhibition and impulsivity were markedly noted in non-demented DS subjects that presented 
one or more changes in behaviour and personality (Ball et al., 2008; Ball, Holland, Hon, et al., 2006). 
Remarkably, 95.7% of those with at least one behavioural change displayed disinhibited behaviour (Ball et al., 
2010). In non-demented DS cohorts, however, disinhibition has hardly been studied. Compared to adolescents 
without DS, those with DS showed more attention problems, which included impulsiveness (van Gameren- 
Oosterom et al., 2013). In addition, Fenner et al. (1987) reported strange and unacceptable (oral) habits, 
eccentric tendencies and improper body exposure, although this was likely related to the hospitalized setting. 
5.9. Euphoria 
Euphoria, like disinhibition is less common in AD than in FTD. As such, the NPI and Middelheim 
Frontality Scale use euphoria as an item to differentiate between AD and FTD (Cummings, 1997; De Deyn et al., 
2005a). De Deyn et al. (2005a) previously reported a prevalence of euphoria in AD patients of 44%, compared 
to 85.5% of the FTD patients. To the best of our knowledge, no reports on euphoria in DS have been published 
so far. 
6. Clinical implications and future perspectives 
BPSD are associated with increased suffering, accelerated cognitive decline, earlier institutionalization 
and an increased mortality risk for patients, increased caregiver burden and higher costs (Finkel, 2000). In that 
context, accurate and early recognition of BPSD in DS may increase awareness and expand our understanding 
of the behavioural aberrations, thus enabling adaptive caregiving and, importantly, allowing for therapeutic 
interventions. 
However, assessment of BPSD in DS is currently undervalued and far from accurate. This primarily 
relates to the evident lack of an all-embracing BPSD scale for DS. Other major issues concern (1) the frequent 
absence of baseline measures of pre-existing behaviour, making it harder to establish the extent of 
deterioration, (2) the variable degree of intellectual disability, i.e. those with severe deficits may not 
understand verbal instructions and cannot (fully) express their feelings, (3) life events that especially affect 
(behaviour of) people with DS, (4) the questionable inter-informant reliability of various scales considering the 
high probability of caregiver changes and (5) a risk of minimization/downplaying of the significance of 
emotional disorders, and overreporting or exaggeration of BPSD (Auer et al., 1996; Aylward, Burt, Thorpe, Lai, 
& Dalton, 1997; Ekstein et al., 2011; Oliver et al., 2011; Prasher, 2009; Reisberg et al., 1996). 
Based on this review, vast experiences in daily clinical practice, and the increased caregiver burden 
related to BPSD, the authors argue that accurate recognition and better evaluation of BPSD in DS are highly 
warranted. Unfortunately, behavioural evaluation scales for AD in the general population do not take the DSspecific 
circumstances into account, and existing scales for dementia in intellectual disabilities, such as the 
commonly used DMR (Evenhuis et al., 1998; Evenhuis, 1996), Cambridge Examination for Mental Disorders of 
Older People with Down Syndrome and Others with Intellectual Disabilities (CAMDEX-DS; Ball, Holland, 
Huppert, Treppner, & Dodd, 2006; Ball et al., 2004) or Dementia Scale for Down Syndrome (DSDS; Gedye, 
1995), are mainly functional and cognitive tools addressing behavioural alterations to a very limited extent. 
Consequently, the authors stress the considerable importance of developing a novel scale for BPSD in 
DS that specifically considers the challenges related to the pre-existing intellectual disability. Since activities of 
daily living, memory, orientation, language and perception are well-covered in the existing cognitive/functional 
DS questionnaires, a scale that exclusively focuses on behaviour would be most suitable. As such, it would 
serve as complementary module to any scale in use, and could thus be easily implemented in assessment 
procedures in routine practice. As described before, individuals with intellectual disabilities have difficulty 
expressing their emotions, causing the assessment of their behaviour to primarily rely on information from 
relatives and caregivers (Moss et al., 1993). Evaluating the pros and cons of patient interviews and informant 
interviews (see also section 3) and drawing on clinical experiences, the authors suggest that a structured, 
informant interview-based tool is the most preferred approach to systematically assess behaviour. Most 
importantly, such a scale should employ an all-embracing approach: not excluding any BPSD item in advance, 
and focussing on the identification of changes over time, i.e. disentangling behavioural alterations from 
characteristic behaviour that has always been typical for an individual. Accordingly, such an evaluation scale 
for BPSD in DS would serve a threefold purpose: (1) as clinical assessment tool to monitor behavioural changes 
in daily care, (2) as research tool in longitudinal follow-up studies, and (3) as comprehensive assessment tool 
for behavioural outcome measures in clinical trials for dementia in DS. 
Firstly, extensive BPSD evaluation during regular follow-up visits, for instance in outpatient clinics, 
permits the identification of increases or decreases in frequency and/or severity of particular behaviour. Since 
BPSD are a major reason for referral (Adams et al., 2008), and caregivers often struggle to understand the 
change (Iacono, Bigby, Carling-Jenkins, & Torr, 2014), this would contribute hugely to improved awareness and 
understanding among relatives and caregivers. Iacono et al. (2014) found that professional caregivers generally 
have a limited understanding of the presentation of AD-related changes in DS, e.g. they often have difficulty 
understanding a resident’s behaviour, and frequently wonder whether (challenging) behaviour is deliberate or  
attributable to dementia. 
Apart from contributing to increased acceptance, meticulous BPSD evaluation would enable timely 
adaptation and optimization of daily caregiving, such as moving someone to a more suitable day-care centre or 
living accommodation, allocating increased time, and differently organizing the daily supervision and care in 
order to improve someone’s personal environment (environmental management; Gauthier et al., 2010). 
Moreover, it would also allow for specific therapeutic interventions. While cognitive deterioration in AD 
cannot yet be prevented, various behavioural, educational and pharmacological options are available to 
reverse or reduce particular BPSD (Gauthier et al., 2010; Nowrangi, Lyketsos, & Rosenberg, 2015). 
Consequently, this would reduce the BPSD-related distress and may improve quality of life. 
But how to select the most appropriate intervention? Iacono et al. (2014) interviewed professional 
caregivers and reported that their management strategies were often based on trial and error. Since 
publications on BPSD management in DS are scarce, studies on management of BPSD in the general AD 
population (extensively reviewed in: Gauthier et al., 2010; Nowrangi et al., 2015) may provide some directions. 
Gauthier et al. (2010) stressed the lack of consensus regarding treatment approaches. Non-pharmacological 
interventions, such as behavioural therapy, psychosocial interventions or music therapy, are generally applied 
first, followed by, or in conjunction with, medication (Gauthier et al., 2010). Although particular BPSD can be 
targeted using specific pharmacological agents, e.g. antidepressants, antipsychotics or anxiolytics, the 
risk/benefit trade-offs have to be carefully assessed. For instance, a recent study with 98 intellectually disabled 
individuals found that discontinuation of antipsychotic treatment for challenging behaviour related to 
improved behavioural functioning (de Kuijper, Evenhuis, Minderaa, & Hoekstra, 2014). 
Secondly, future longitudinal studies using a specific evaluation scale for BPSD in DS would allow for 
the establishment of the temporal relationship between the presence of particular BPSD and the moment of 
the clinical diagnosis of AD dementia in DS. Accordingly, this enables the identification of particular BPSD as 
early behavioural indicators for clinical AD (Jost & Grossberg, 1996), possibly corroborating the 
aforementioned findings of frontal lobe symptoms as early changes of AD in DS. Such longitudinal approaches 
are highly necessary, since only sustained follow-up studies (multiple years) may identify predictive symptoms, 
as demonstrated by our group in a ten-year follow-up study of an AD cohort in the general population 
(Engelborghs et al., 2005; Van der Mussele, Fransen, et al., 2014; Van der Mussele, Mariën, et al., 2014a). 
Finally, an all-embracing scale for BPSD in DS could greatly improve the monitoring of behavioural 
outcome measures in clinical trials. In the general AD population, the BEHAVE-AD and NPI are frequently used 
in large-scale clinical trials for new psychotropic medication (Cumbo & Ligori, 2014; De Deyn & Wirshing, 2001; 
Porsteinsson et al., 2014; Sultzer et al., 2008). For instance, risperidone, an atypical antipsychotic drug, has 
been previously demonstrated to significantly reduce agitation, aggression and psychosis-associated 
symptoms in AD patients in the general population, as well as reduce overall BEHAVE-AD scores, which is 
indicative of an improving BPSD profile (De Deyn et al., 1999, 2005b; Rabinowitz et al., 2007). In agreement, 
others reported that risperidone treatment of AD patients resulted in reduced NPI total scores, which, again, 
indicates beneficial symptomatic effects on the overall presence of BPSD (Sultzer et al., 2008). 
Currently, two phase II clinical trials on cognitive enhancement in DS are ongoing: one using the green 
tea flavonol epigallocatechin-3-gallate (EGCG) (De la Torre et al., 2014; Parc de Salut Mar, 2012: NCT01699711) 
and the CLEMATIS study using the GABAA α5 receptor inverse agonist RG1662 (Ballard et al., 2009; Hoffmann- 
La Roche, 2013: NCT02024789). Importantly, behaviour is included in the primary outcome measures in both 
trials. More specifically, the EGCG trial uses ‘change in cognitive evaluation’, which includes a neuropsychiatric 
evaluation based on, amongst others, DMR and NPI scores. The RG1662 study evaluates adaptive behaviour. 
Whereas both trials focus on cognitive enhancement with respect to the congenital intellectual disability, the 
EGCG trial also evaluates the effect of EGCG on the deceleration of AD progression in DS. Despite the fact that 
the DMR (not inclusive) and NPI (not adapted) sub-optimally assess BPSD in DS, these scales remain to be 
employed given the lack of more optimal measures. Therefore, a novel, comprehensive scale to assess BPSD in 
DS would be very valuable. 
7. Neurobiology of BPSD in DS 
Unravelling the underlying neurobiological mechanisms of BPSD in DS would contribute to the general 
understanding of these burdensome behavioural and psychological changes and aid the development of 
targeted therapeutic, and possibly preventive, interventions. An increasing number of studies addressed the 
mechanisms of BPSD in AD, for instance pointing at specific dysregulated monoaminergic neurotransmitter 
systems (Vermeiren et al., 2014a, 2014b). In agreement, we recently reported multiple correlations between 
monoaminergic changes in serum of demented, converted and non-demented DS subjects and individual BPSD 
items (Dekker et al., 2015). Furthermore, GABAergic neurotransmission appears to be altered in DS brain and 
has been implicated in learning and memory deficits (reviewed in: Martínez-Cué et al., 2014). GABA is the 
major inhibitor neurotransmitter in the adult forebrain, and as such, its altered neurotransmission will likely 
affect behaviour as well. 
In addition, frontal lobe dysfunction has been suggested as early manifestation of AD in DS (Ball et al., 
2008; Ball, Holland, Hon, et al., 2006; Deb et al., 2007; Nelson et al., 2001). Indeed, it is thought that lesions in 
the complex frontal-subcortical neuronal circuits cause particular behavioural alterations, i.e. impairment of 
the anterior cingulated circuit is associated with apathy, lesions in the lateral orbitofrontal circuit cause 
disinhibition and reduced empathy, and disruption of the dorsolateral prefrontal circuit relates to executive 
dysfunction (Tekin & Cummings, 2002). This led Ball and co-workers to suggest that ‘the serotonergicallymediated 
orbitofrontal circuit may be disproportionally affected’ in DS as disinhibited behaviour was markedly 
present, relative to the apathy and executive dysfunction, in non-demented DS subjects with one or more 
behavioural change(s) (Ball et al., 2010), thus again pointing in the direction of altered neurotransmission. 
Alternatively, the symptoms related to frontal lobe dysfunction in DS might be explained by preexisting 
abnormalities in the DS brain, which may modulate the effect of AD dementia on behavioural changes 
associated with prefrontal cortex functioning. Indeed, people with DS have a reduced volume of the frontal 
cortex (Beacher et al., 2010) and therefore only a small additional neuropathology, such as accumulation of 
Aβ, may have a makeable impact in its functionality (Lott & Head, 2001). For this reason functional 
impairments of frontal cortical regions may coexist with the development of AD in DS. 
Although mechanisms similar to those in AD patients may underlie BPSD in DS, the supplementary 
effect of the overexpressed chromosome 21 gene products has not yet been investigated. In addition to their 
altered genetics, mounting evidence suggests the presence of epigenetic aberrations in DS, which appear to be 
important factors in the development of the cognitive deficits in DS (Dekker, De Deyn, & Rots, 2014) and might 
also affect DS behaviour. Future studies that specifically address DS, taking their unique genetic background 
into account, are necessary to further elucidate the neurobiology of BPSD in DS. 
8. Conclusion 
In conclusion, BPSD are a core symptom of dementia in addition to cognitive decline and impaired 
activities of daily living, and are extensively studied in MCI and AD patients in the general population. Despite 
the extremely high risk to develop AD and the lack of early (bio)markers with limited invasiveness to predict 
the onset of AD in DS, most dementia research in the DS population did not comprehensively assess BPSD. The 
great variety of cohorts, diagnostic methodologies, covariates and outcome measures that have been used in 
the available BPSD studies in DS yielded diverse results and made comparisons generally hard to accomplish. 
Due to the multitude of applied, sub-optimal scales, it is questionable whether BPSD have always been 
accurately assessed, for instance regarding the differential diagnosis between apathy and depression. Interstudy 
comparisons are additionally complicated by the fact that control groups varied between these studies, 
from non-demented DS individuals and intellectually disabled persons with other aetiologies, to AD patients in 
the general population. 
Various BPSD appear to be altered in demented DS individuals, but study results have not always been 
consistent. Based on the existing literature, Figure 1 summarized the temporal relationship between BPSD and 
the clinical diagnosis of AD. From childhood to adulthood, externalizing behaviour likely decreases and 
internalizing behaviour increases. Frontal lobe symptoms have been suggested as early signs of AD in DS. 
Indeed, disinhibition and apathy, as well as executive dysfunction, seem to be omnipresent in the prodromal 
phase, whereas reports are still too divergent to assume that this is also true for depression. Regarding activity 
disturbances, various studies indicated decreasing hyperactivity levels towards adulthood in DS. Excessive 
activity in demented DS individuals would thus be a fairly easy observable sign. However, general slowness in 
this group has been reported as well. In addition, the presence of apathy itself might cause reduced activity. 
Agitation appears to be more prevalent in demented than in non-demented DS individuals, but reports on 
aggression are inconsistent, though aggression seems to be reduced in the overall DS population. Sleep 
disturbances are markedly present in both demented and non-demented DS individuals. Although sleep 
disorders may not yet differentiate between those with and without AD, they are important to consider as 
such sleep disorders may aggravate cognitive decline and BPSD. Next, a higher prevalence of psychotic 
symptoms (delusions and hallucinations) is likely observed in DS persons with dementia than among those 
without dementia. Finally, anxiety and phobias, appetite and eating abnormalities and euphoria have been 
hardly studied in DS and DS-AD. 
Taken together, the need for a validated and comprehensive scale for BPSD in DS is evident. The 
limited current understanding and the vast amount of (inconsistent) reports discussed in this review illustrate 
the vital importance for an all-inclusive scale that does not omit specific BPSD items in advance, and that 
focuses on individual changes over time, disentangling those changes from someone’s typical behaviour. Once 
BPSD can be meticulously assessed in DS, longitudinal studies are of utmost importance to establish the 
temporal relationship between BPSD and the clinical dementia diagnosis, likely revealing early signs of AD in 
DS. Such signs are of great value, as they may serve as early clinical indicators for AD in DS, thereby enabling 
adaptive caregiving and early therapeutic interventions. 
CAPTION FIGURE 1 
Fig.1: Temporal relationship between BPSD and the clinical diagnosis of AD in DS. From childhood towards 
adolescence and early adulthood, externalizing behaviour decreases and internalizing behaviour increases. In 
non-demented adults with DS, apathy, disinhibition and executive dysfunction have been reported as early 
behavioural symptoms, possibly predictive for the onset of dementia. Agitation, hyperactivity/general 
slowness and psychotic symptoms seem to be more prevalent in demented DS individuals. Sleep disturbances 
have been described throughout life. Anxiety and phobias, appetite and eating abnormalities and euphoria 
have been hardly studied in DS and DS-AD. 
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Table 1: Overview of BPSD items in BEHAVE-AD and NPI scales 
Behavioural Pathology in Alzheimer's Disease Rating Scale 
(BEHAVE-AD) 
Neuropsychiatric Inventory (NPI) 
Activity disturbances 
Incl. purposeless activity, inappropriate activity, wandering 
Aberrant motor behaviour 
Affective disturbances 
Incl. depression, tearfulness 
Apathy 
Depression/dysphoria 
Aggressiveness 
Incl. agitation, physical aggression, verbal aggression 
Agitation/aggression 
Irritability/lability 
Anxieties/phobias Anxiety 
Diurnal rhythm disturbances Night-time behaviour disturbances 
Hallucinations 
Incl. auditory, haptic, olfactory and visual hallucinations 
Hallucinations 
Paranoid and delusional ideation 
Incl. delusions of all kinds, like stealing and abandonment 
Delusions 
Appetite/eating disturbances 
Disinhibition 
Euphoria/elation 
(Cummings, 1997; Cummings et al., 1994; Kaufer et al., 2000; Reisberg et al., 1987; Reisberg, Auer, & 
Monteiro, 1996) 
 
 
 
 
 
  
  
  
